Introduction
Cervical cancer is a leading neoplastic disease that inflicts women worldwide. An etiologic relation between high-risk human papillomavirus (HPV) and cervical cancer has been firmly established (Zur Hausen, 2002) . The local immune system of the genital tract is assumed to be important in the monitoring of HPV-related cervical cancer. Consequently, various cytokines have been implicated in the pathogenesis of cervical cancer, among which interleukin-6 (IL-6) has received particular attention. Epidemiologic studies have shown that the development of cervical cancer is associated with chronic inflammation resulting from multiple sexually transmitted agents (Schiffman and Brinton, 1995) . Viral infection and exposure to proinflammatory cytokines such as IL-1a and tumor necrosis factor a can stimulate IL-6 gene expression by the keratinocytes (Iglesias et al., 1995) . IL-6 expression in tumor tissues is high and correlates with the severity of cervical cancer (Tartour et al., 1994; Tjiong et al., 1999; Wei et al., 2001a) . Also, IL-6 may contribute to a local immunosuppressive effect that protects the tumor cells from the host immune system (Tilg et al., 1997) . These works support the hypothesis that IL-6 promotes the development of cervical cancer, although the underlying mechanism remains elusive.
IL-6 is a secreted, multifunctional glycoprotein. Through binding to a-chain (IL-6-R, gp80) and subsequently recruiting the b-chain (gp130) of the receptor, IL-6 performs various biological functions . Specifically, the IL-6/IL-6R complex initiates homodimerization of gp130, activates a cytoplasmic tyrosine kinase bound to gp130 (Murakami et al., 1993) , and then triggers signaling cascades through the Jak/STAT, Ras/MAPK, and PI 3-K/Akt pathways (Hirano et al., 1997) . The diversity of IL-6 signaling mediated via gp130 explains its functional pleiotrophy. IL-6 regulates inflammatory reactions, immune responses, hepatic acute-phase protein synthesis, and several other important physiological processes (Taga and Kishimoto, 1997) . Interestingly, the influence of IL-6 in human cancers is varied depending on the cell types. For example, IL-6 has been demonstrated to promote growth of multiple myeloma, Kaposi's sarcoma, and prostatic cancer cells, while inhibiting the proliferation of lung and breast cancer cells (Danforth and Sgagias, 1993; Takizawa et al., 1993; Klein et al., 1995; Nicholas et al., 1997; Okamoto et al., 1997) .
Angiogenesis is essential for the development, growth, and progression of cervical cancer (Sillman et al., 1981; Smith-McCune and Weidner, 1994; Hanahan and Folkman, 1996; Smith-McCune et al., 1997) . The angiogenic process is balanced by various positive (such as bFGF, vascular endothelial growth factor (VEGF), and PD-ECGF) and negative (such as thrombospondin-1, platelet factor-4, and interferon a/b) regulatory molecules of endothelial proliferation and migration (Carmeliet, 2000) . Previous investigations have confirmed that IL-6 is important in both physiological and pathological angiogenesis (Motro et al., 1990; Mateo et al., 1994; Mahnke et al., 2000) . Additionally, recent study has identified that STAT3 is a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers (Niu et al., 2002) . These studies raised the possibility that elevated IL-6 in the uterine cervix promotes the development of cervical neoplasm via angiogenesis stimulation.
This work focused on the angiogenic and tumorigenic potential of IL-6-overexpressed C33A cervical cancer cells. The experimental results revealed that IL-6-overexpressed C33A cells displayed accelerated tumor growth and neovascularization in nude mice. Furthermore, blockage of VEGF function was found to inhibit IL-6-mediated angiogenesis and reduce IL-6-induced tumor growth in nude mice. IL-6 specifically upregulates VEGF in C33A cells via a STAT3 pathway. Earlier studies have demonstrated consistently higher expression of IL-6 and VEGF in cervical cancer tissues (Wei et al., 2001a) . Therefore, we believe strong evidence exists to support the hypothesis that IL-6 facilitates tumorigenesis of cervical cancer via VEGF-mediated angiogenesis.
Results

Growth properties of IL-6-overexpressed cervical cancer cells
Five C33A clones with stable IL-6 gene transfection were established and designated as C33A/IL-6 cells (C33A/IL-6-c1, -c2, -c3, -c4, and -c5), while these with control vector were designated as C33A/neo cell. ELISA confirmed that C33A/IL-6 cells produced significantly higher levels of IL-6 (>2,000 pg/ml) than did C33A/neo cells (o50 pg/ml). Neither the IL-6-overexpressed cells nor the neo control cells caused changes in IL-6 receptor levels, which were measured by immunoblotting with an antibody that recognized the ligand-binding subunit of the IL-6 receptor (Wei et al., 2001b) . Also, the in vitro cell proliferation of C33A/IL-6 and C33A/neo cells was examined by counting cells. Figure 1a shows that IL-6 overexpression does not substantially alter the rate of growth in C33A cells. The MTT assay was used in conjunction with trypan blue counting. Results from the analysis revealed that IL-6-overexpressed C33A cells have similar in vitro growth kinetics as compared to their neo controls (Figure 1b) . Additionally, treatment with exogenous IL-6 did not influence the proliferation rate of parental C33A cells (data not shown). Collectively, the above results suggest that overexpression of IL-6 does not affect receptor levels and anchoragedependent growth in C33A cells.
IL-6 accelerated tumor growth in nude mice
Next, the influence of IL-6 on in vivo tumorigenesis was examined. Two IL-6-overexpressed cells (C33A/IL-6-c1 and -c5) and neo control cells were subcutaneously injected into 4-5-week-old nude mice. Then tumorigenicity was assessed weekly according to tumor volume. The tumors derived from C33A/IL-6-c1 cell grew faster than those from C33A/neo cell after 2-3 weeks of initial development. The mean tumor size in C33A/IL-6-c1 transplanted nude mice was around 3500 mm 3 at the sixth week post-transplantation, but in nude mice injected with C33A/neo cells the mean tumor size reached merely 1100 mm 3 ( Figure 1c ). In a separate experiment, the mean volume of C33A/IL-6-c5 tumors grew to a size similar to C33A/IL-6-c1 tumors at the sixth week and was approximately seven times the size of C33A/neo tumors at the eighth week after transplantation ( Figure 1d ). These experimental results clearly verify that IL-6 overexpression can enhance in vivo tumor growth of C33A cervical cancer cells without significantly altering their in vitro growth rate.
Angiogenic activity of C33A cells is augmented by IL-6
Angiogenesis is a prerequisite to the rapid clonal expansion associated with the formation of macroscopic tumors. Gross examination of the peripheral segments of C33A xenografts revealed that the tumors produced by the IL-6-overexpressed C33A cells were highly vascularized, whereas those produced by the C33A/neo cells displayed slight new blood vessel growth (data not shown). The in vivo model of chick embryo chorioallantoic membrane (CAM) assay can be used to clarify the influence of IL-6 on cervical tumor angiogenesis. Upon dissection of the CAM of a 12-day-old chick embryo, low angiogenic activity in CAM was observed using the conditioned medium (CM) from parent C33A or neo control cell cultures (Figure 2a) . Importantly, high angiogenic activity was found on CAM treated using CM from IL-6 transfectant. To quantify the different types of tumor angiogenic activity before the appearance of a grossly visible tumor, in vivo Matrigel plug assays were performed. The experimental results revealed that CM from IL-6-overexpressed cells displayed more vascularization in the matrigel plug on the 7th day after inoculation (Figure 2b, left) . The degree of vascularization can be measured based on the hemoglobin contents (Figure 2b , right). These biological assays confirm that IL-6 may increase angiogenic activity in human cervical cancer cells.
Upregulation of VEGF by IL-6 in cervical cancer cells and tumors
Reverse transcription-polymerase chain reaction (RT-PCR) was used to assess expression of various angiogenic factors, including VEGF, bFGF, PDGF, and IL-8, that previously have been reported to contribute to tumor angiogenesis in cervical cancer (Fujimoto et al., 1997 (Fujimoto et al., , 1999a (Fujimoto et al., , 2000 Cheng et al., 1999; Kodama et al., 2001 ). Of the genes tested, VEGF-A mRNA, but not other factors, was elevated in IL-6-overexpressed C33A cervical cancer cells ( Figure 3a ). Consistent with the mRNA level, CM contained a significant amount of VEGF-A protein from IL-6-overexpressed C33A cells (Figure 3b ). Moreover, the gene expression of VEGF was measured in tissue from C33A/neo and C33A/IL-6 tumors transplanted to nude mice. RT-PCR revealed that tumors from the IL-6-overexpressed C33A cells had significantly higher VEGF mRNA levels than those from neo control cells ( Figure 3c ). These experimental results indicate that VEGF is the major mediator of IL-6-induced tumor angiogenesis. 
Blockage of VEGF function inhibits IL-6-mediated angiogenesis and inhibits IL-6-induced tumor growth in nude mice
To clarify whether VEGF influenced IL-6-mediated tumorigenesis, 10 mg/kg anti-VEGF antibody was intraperitoneally injected on alternate days specifically to block VEGF function in nude mice transplanted with IL-6-overexpressed C33A cells. From the second week after tumor inoculation, tumor growth was significantly delayed in the anti-VEGF-antibody-treated group Figure 2 Effect of IL-6 on angiogenic activity of C33A cervical cancer cells. (a) CAMs of 10-day-old chick embryos were incubated with DMEM as a negative control (I), conditioned medium (CM) from parental C33A (II), neo control (III), C33A/IL-6-c1 (IV), C33A/IL-6-c5 (V), or VEGF 100 ng/disk as a positive control (VI) for 48 h, and then resected, fixed, and photographed with a stereomicroscope at Â 9 magnification. (b) Subcutaneous Matrigel plug assay was conducted by injecting 75 ml of CM mixed with 425 ml Matrigel and 50 U heparin/ml into nude mice (10 mice/group). After 6 days, the mice were killed and dissected. Left, gross appearance of Matrigel plug retrieved from nude mice (I-III, C33A/IL-6-c5, neo control, DMEM). Right, neovessels were measured using hemoglobin levels of the plug with the Drabkin reagent kit 525. Each value is a mean7s.d. obtained from 10 mice Interleukin-6 activates cervical tumor angiogenesis L-H Wei et al ( Figure 4a ). The tumors in the C33A/IL-6-c5 and control mouse IgG antibody groups (10 mg/kg) grew steadily during the experiment, but those in the anti-VEGF-antibody-treated group did not. On day 29 after tumor implantation, the tumor weight was 4375 mg in the anti-VEGF antibody group compared to 6257155 mg in the untreated group (Po0.003) and 201750 mg in the control antibody group (Po0.006). Meanwhile, the tumor weight in the C33A/neo group reached just 123758 mg. Furthermore, the relative mRNA expression of mouse platlet/endothelial cell adhesion molecule-1 (PECAM-1) in C33A/IL-6-c5 and C33A/neo tumors was examined using RT-PCR. The experimental results revealed that expression of PE-CAM-1 mRNA was considerably upregulated in C33A/ IL-6-c5 tumors (Figure 4b ), which was consistent with the more vascularized appearance of IL-6-overexpressed tumors. Treatment with anti-VEGF antibody led to a marked downregulation of PECAM-1 mRNA expression in the C33A/IL-6-c5 tumors as compared to the control antibody ( Figure 4b ). These works indicate that VEGF is responsible for IL-6-mediated tumor growth.
STAT3 pathway is essential for VEGF upregulation by IL-6
To define the signaling pathway involved in transcriptional upregulation of VEGF by IL-6, C33A cells were treated with different pharmacological inhibitors. Treatment with PD98059 and LY294002, which specifically inhibit MEK1 and PI3-K respectively, did not influence IL-6-mediated upregulation of VEGF mRNA expression ( Figure 5a ). Consequently, the involvement of the STAT3 pathway in the IL-6-mediated VEGF upregulation was examined. To address this issue, control vector and STAT3 dominant-negative mutant (STAT3D), in which E434 and E435 of STAT3 were replaced with alanines (Horvath et al., 1995) , were introduced into C33A cells. As shown in Figure 5b , transfection of STAT3D in C33A cells significantly inhibited the VEGF mRNA expression as compared to the parent C33A and neo control cells, suggesting that STAT3 is crucial to the IL-6-mediated VEGF upregulation. Since tissue hypoxia is a potent inducer of VEGF induction, luciferase reporter gene assay was used to examine whether the IL-6 upregulated VEGF through a hypoxia-dependent mechanism. Figure 5c indicated that only the 1.5 kb promoter responded to cobalt chlorides, but both the 1.5 and 1.2 kb (lacking HIF-1 biding site) promoters of VEGF were markedly activated by IL-6 treatment, suggesting that IL-6 is capable of stimulating VEGF promoter through a HIF-1-independent mechanism. However, when STAT3D transiently transfected into C33A cells (transfection efficiency, 20%), the activation of VEGF promoter by IL-6 reduced significantly (Figure 5d ).
Coexpression of IL-6 and VEGF in human cervical cancer
The close association between IL-6 and VEGF revealed above prompted investigation of the expression of IL-6 Figure 3 (a) Expressions of angiogenic factors in IL-6-overexpressed C33A cells were identified using RT-PCR. CDNA, derived from mRNA extracted from IL-6 transfectants or vector control, was amplified by PCR using primers specific for VEGF, bFGF, PDGF, and IL-8. The PCR products were loaded onto 2% agarose gel and confirmed by ethidium bromide staining. b-actin was used as an internal control. (b) VEGF-A proteins of the cell culture supernatant were identified by enzyme immunoassay.
(c) RT-PCR verified IL-6 and VEGF mRNA levels in xenografts derived from C33A/IL-6-c5 or C33A/neo cells transplanted in nude mice
Interleukin-6 activates cervical tumor angiogenesis L-H Wei et al and VEGF in cervical cancer tissues. To address this issue, biopsies of cervical cancer tissues and adjacent noncancer tissues were taken from four patients with invasive cervical cancer to analyse the levels of IL-6 and VEGF proteins by Western blot analysis. Figure 6 displayed that both IL-6 and VEGF expressions were significantly more abundant in cancer tissues than in noncancer tissues. This finding provides clinical evidence to support a close relation between IL-6 and VEGF in the development of cervical cancer.
Discussion
Various arguments have suggested that IL-6 is important in cervical carcinogenesis because it is a central proinflammatory cytokine involved in female genital infection and is abundant in the microenvironment of cervical cancer (Tartour et al., 1994; Richter et al., 1999; Tjiong et al., 1999) . However, the critical pathophysiological mechanism for IL-6 in the development of cervical cancer remains uncertain owing to its functional pleiotropy and redundancy. Our previous work demonstrated that IL-6 facilitates the oncogenesis of human cervical cancer by modulating the apoptotic threshold via a PI3-K/Akt-dependent pathway (Wei et al., 2001b) . The present study reveals a distinct function of IL-6 signaling in cervical cancer, namely the regulation of the angiogenic switch. This study transfected IL-6 gene into an IL-6 null cervical cancer cell line C33A and confirmed that IL-6 expression promotes cervical tumor growth in nude mice. Although previous studies showed that IL-6 could promote the growth of both normal and neoplastic cervical epithelial cells (Eustace et al., 1993; Castrilli et al., 1997) , IL-6 appeared to play a limited role in the proliferation of C33A cervical cancer cells because all the parental, neo control, and IL-6-overexpressed C33A cells displayed similar in vitro growth kinetics ( Figure  1a, b) . Our experimental results provide evidence that IL-6 promotes cervical tumorigenesis by activating Figure 4 Effects of anti-VEGF treatment on C33A/IL-6 xenograft in nude mice. (a) C33A/IL-6-c5 cells were injected subcutaneously in the dorsal area. Treatment (n ¼ 5 per group) was begun after day three by i.p. administration of 10 mg/kg anti-VEGF antibody on alternate days. The volume of the tumor was measured as described in Materials and methods. (b) After 28 days, the animals were killed and neovascularization of xenografts (I-IV, C33A/neo, C33A/IL-6-c5, C33A/IL-6-c5+anti-VEGF Ab, C33A/IL-6-c5+IgG) was assessed by RT-PCR with mouse PECAM-1 specific primer Interleukin-6 activates cervical tumor angiogenesis L-H Wei et al tumor-derived VEGF-dependent angiogenesis. Supporting evidences were obtained from previous works on head and neck cancer, multiple myeloma, basal cell carcinoma, and Kaposi's sarcoma (Aoki et al., 1999; Dankbar et al., 2000; Jee et al., 2001) . VEGF is a potent angiogenic factor that is pivotal in the transition from an avascular tumor to a vascularizing phenotype tumor (Ferrara and Davis-Smyth, 1997) . VEGF expression has been reported to be associated with the progression of cervical intraepithelial neoplasia (Guidi et al., 1995; Dobbs et al., 1997) , the angiogenesis and early invasion of cervical cancer, and the prognosis of patients with early-stage cervical cancer (Kodama et al., 1999; Cheng et al., 2000) . Given the importance of VEGF in the development of cervical cancer, clarifying the cellular factors responsible for its regulation may provide molecular therapeutic targets for cervical cancer.
In cervical cancer, VEGF is derived mainly from the tumor cells rather than the stromal cells (Fujimoto et al., 1999b) . Several oncogenes have been identified as potential inducers of VEGF expression. For example, c-erb-B-2 is likely to be involved in the upregulation of VEGF expression in cervical adenocarcinoma (Lee et al., 2002) . Moreover, HPV oncoprotein E6, which has been
Figure 5 IL-6 upregulates VEGF through a STAT3 pathway that is independent of the hypoxia response element. (a) PI3-K or MAPK pathway is not involved in the upregulation of VEGF by IL-6. C33A cells were pretreated with 50 mm LY294002 or PD98059 for 1 h before IL-6 stimulation (50 ng/ml). Upper blot, IL-6-induced Akt and Erk1/2 phosphorylation were determined 1 h after IL-6 stimulation by Western blot. Lower blot, effect of LY294002 or PD98059 on IL-6-mediated VEGF mRNA expression was determined 6 h after IL-6 stimulation by Northern blot. (b) Dominant-negative STAT3 (dnSTAT3) inhibits IL-6-induced VEGF upregulation. C33A cells were transfected with dnSTAT3 or control vector. After G418 selection, stably expressed dnSTAT3 or neo control cells were treated with or without IL-6 (50 ng/ml) for 6 h before total RNA extraction. (c) Effect of IL-6 on VEGF promoter activity. C33A cells were transfected with 1.5 or 1.2 kb of the VEGF promoter construct that lacks the HIF-1 binding site. After 24 h of transient transfection, the cells were treated with or without IL-6 (50 ng/ml) for 6 h, and luciferase activities were measured. (d) Effect of dnSTAT3 (STAT3D) on VEGF promoter activity. C33A cells were cotransfected with STAT3D or control vector, and 1.2 kb of the VEGF promoter construct. The cells were harvested 6 h after transfection and luciferase activities were measured Interleukin-6 activates cervical tumor angiogenesis L-H Wei et al etiologically linked to cervical cancer, may directly activate the VEGF promoter in a p53-independent manner (Lopez-Ocejo et al., 2000) . Interestingly, hypoxic stress, a common environmental feature of solid tumors, has been demonstrated to induce IL-6 expression in vascular cells and cardiomyocytes (YamauchiTakihara et al., 1995; Yan et al., 1995) , implying that IL-6 may be an important mediator in hypoxia-induced angiogenesis during rapid tumor growth. IL-6 is a key microenvironmental influence in cervical cancer, and is produced in different types of cells in cervical cancer, including tumor cells, fibroblasts, macrophages, and monocytes (Belec et al., 1995; Iglesias et al., 1995; Tartour et al., 1994; Wei et al., 2001a) . Accordingly, the data herein indicated that IL-6 may transcriptionally upregulate VEGF expression in cervical cancer cells via an autocrine and/or paracrine mechanism.
The mechanisms underlying the induction of VEGF mRNA by IL-6 remain unclear. Binding of IL-6 and its receptor initiates homodimerization of gp130 and then triggers signaling cascades through the Jak/STAT, Ras/ MAPK, and PI3-K/Akt pathways (Hirano et al., 1997) . The PI3-K/Akt, a common signaling pathway for oncogene and growth factors, is involved in the regulation of VEGF by controlling levels of hypoxiainducible factor 1 (Jiang et al., 2001) . Additionally, the ERK1/2 MAPK signaling pathway has been verified to be involved in the low pH-induced VEGF (Xu et al., 2002) . However, the experimental results herein have confirmed that STAT3-, but not PI 3-K or MAPK, dependent pathway is essential to the regulation of VEGF mRNA by IL-6 in cervical cancer cells. Earlier studies have obtained similar results, showing that constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis (Niu et al., 2002) . Constitutively activated STAT3 has been detected in cervical cancer cells, although its role in signaling multistage cervical carcinogenesis remains unknown (Page et al., 2000) . The IL-6/gp130/STAT3 signaling pathway is essential for cell survival, G1 to S cell-cycle transition, cell differentiation, and cell movement, thereby participates in oncogenesis of hematopoietic cells (Hirano et al., 2000) . The present study reveals that IL-6 is capable of driving VEGF promoter independently of hypoxic-response elements via a STAT3 pathway, supporting that STAT3 contributes to cervical carcinogenesis and represents a common angiogenic mediator induced by multiple signaling pathways in human cancers (Niu et al., 2002; Valdembri et al., 2002) .
In summary, this work is the first to demonstrate that IL-6 is involved in the complex regulatory mechanism that activates angiogenesis and thus promotes tumorigenesis of cervical cancer. The data presented here suggest that therapeutic approaches targeting IL-6/IL-6R may have the additional benefit of reducing tumor angiogenesis, and may shed light on a novel preventive and therapeutic approach for human cervical cancer.
Materials and methods
Establishment of IL-6 transfectants
The human cervical cancer cell line C33A, obtained from American Type Culture Collection (Manassas, VA, USA), was cultured at 371C and 5% CO 2 in DMEM supplemented with 10%(vol/vol) fetal bovine serum (FBS). C33A is an HPVnegative cervical cancer cell line and unable to produce IL-6. The pCMV-IL-6, a constitutive expression vector, carries 0.64 kb full-length human IL-6 cDNA under control of the CMV promoter/enhancer sequence. The pCMV-IL-6 or pCMV was transfected into C33A cell line by using the TransFastt transfection reagent (Promega). After 24 h, cells were replated in DMEM with 10% FCS and 200 mg/ml G418. G418 resistant clones were selected and expanded.
Antibodies and reagents
Recombinant human IL-6, VEGF, antibodies to human IL-6, bFGF, and VEGF were obtained from R&D system. Antibodies to STAT3, ERK, p-ERK, and Ang-2 were obtained from Santa Cruz Biotechnology. Antibodies to Akt and p-Akt were from Upstate Biotechnology. Mouse IgG, CoCl 2 , and the kinase inhibitors, such as LY294002 and PD98059, were from Sigma. Mammalian expression plasmid for the dominant-negative mutants of STAT3, STAT3D, was kindly provided by Dr T Hirano.
Enzyme immunoassay
The IL-6 and VEGF levels of the cell culture supernatant were determined via enzyme immunoassay with commercially available kits (R&D Systems). Each measurement was repeated in triplicate, and the average value was recorded as pg/ml.
Cell proliferation
Cells were plated onto six-well cell culture plates at 20 000 cells/well in 2 ml of culture medium with FBS. At 24, 48, and 72 h of treatment at 371C, the cells were harvested by suspension in 0.025% trypsin in 0.02% EDTA solution. Cell counts were performed in triplicates using a hemocytometer, Figure 6 Expression of angiogenic factors in biopsy from human cervical cancer patients. Western blot analysis of various angiogenic factors in cancer tissue (T) and adjacent noncancer tissue (N) derived from four patients with invasive cervical cancer. Each tissue was homogenized and extracted, and equal amounts of protein extracts were subjected to immunoblotting. a-tubulin was used as an internal control Interleukin-6 activates cervical tumor angiogenesis L-H Wei et al with trypan blue exclusion to identify viable cells. Growth curves were generated for each cell line.
MTT assay
Cells were plated into 96-well microplates at a density of 5 Â 10 3 cells/well for cell viability assay. Briefly, the cells were cultured at 371C for the indicated time, and 30 ml of MTT solution (5 mg/ml) was added into each well, then incubated for 4 h in darkness. The formazan grain was then dissolved in DMSO, and the absorbance at 570 nm was read using an ELISA plate reader.
Tumorigenicity assay in nude mice
Nude mice were purchased from National Health Research Institute (Taipei, Taiwan), housed in a dedicated nude mouse facility with microisolator caging. Control-transfected C33A cells and IL-6-transfected C33A cells were trypsinized, washed with PBS, resuspended in DMEM, and adjusted to a concentration of 2 Â 10 6 cells/250 ml in DMEM. Then the cell suspensions were mixed with 250 ml Matrigel and injected subcutaneously into nude mice. Tumor development was followed in individual animals (5-8/group) by weekly sequential caliper measurements of length (L) and width (W). Tumor volume was calculated by the formula LW 2 /2. After the indicated time, the mice were killed; the tumors were removed and weighed. A segment was excised and fixed in 10% neutral buffered formalin.
Preparation of (CM)
Cultures of the various cervical cancer cells were rinsed twice with PBS and cultured in 10 ml of serum-free DMEM. Cervical cancer cell CM was collected after a 24 h incubation, and 25 mm HEPES buffer (pH 7.4), 1 mg/ml leupeptin, 1 mm phenylmethylsulfonyl fluoride, 1 mm EDTA, 0.02% NaN 3 , and 0.1% BSA (Sigma) were added. Cervical cancer cell CM was clarified by centrifugation. CM was frozen and stored at À701C until use.
Angiogenesis assays in vivo
Eggs of 10-day-old chick embryos (10 per group) were opened into a 1.0-cm 2 window that allowed direct access to underlying CAM by the method described previously (Masood et al., 1999 ). An 8 mm filter paper disk (Advantec, Japan) saturated with various cervical cancer cell CM was applied to the top of CAM. Filter paper disks saturated with VEGF as positive controls (200 ng per disk) or an equal amount of carrier buffer as negative control was placed on the CAMs. The window was covered with sterile cellophane tape, and the embryos were incubated for a further 48 h at 371C with 60% humidity to develop spontaneous angiogenesis. CAMs were harvested and analysed using a stereomicroscope.
Quantitation of angiogenesis was performed by mouse Matrigel plug assay as described previously (Passaniti et al., 1992) . Briefly, nude mice (10 per group) were each injected subcutaneously with 75 ml of CM from various cervical cancer cell lines mixed with 425 ml Matrigel (10.6 mg/ml; Becton Dickinson Labware) and 50 U heparin/ml at 41C. Mice were subsequently killed 6 days later, and gels were recovered and processed for further studies. Neovessels was quantified by measuring hemoglobin of the plug with the Drabkin method and Drabkin reagent kit 525 (Sigma).
RT-PCR
The RT-PCR was performed using an RT-PCR kit (LIFE Technologies). The sequences of the primers were as follows; mouse platelet/endothelial cell adhesion molecule-1 (PECAM-1) (581C): sense 5 0 -CGT CTG GAC CTG GCT GGC CGG GAC C-3 0 and antisense 5 0 -CTA GAA GCA TTT GCG GTG GAC GAT G-3 0 ; and GADPH (551C): sense 5 0 -GAA GGT GAA GGT CGG AGT CAA-3 0 and antisense 5 0 -GCA GAG GGG GCA GAG ATG AT-3 0 . A total of 30 cycles were performed with each cycle consisting of 1.5 min at 721C, 1 min at 941C, and 1 min at 55-581C depending on each gene, with a final extension of 8 min at 721C. All amplifications were carried out within the linear range of the assay, and human b-actin reactions were amplified for 25 cycles. The reaction products were separated on 2% agarose gel and stained with 1 mg/ml ethidium bromide and quantified by IS-1000 Digital imaging system, the results were confirmed in at least three replicate experiments.
Northern blot analysis
Total RNA was extracted using the RNAzol B reagent (Biotecx Laboratories). Total RNA samples (20 mg each) prepared from the cell lines were electrophoresed under denaturing conditions with formaldehyde in 0.8% (w/v) agarose gel. The separated RNAs were transferred to nylon membranes (positively charged; Boehringer Mannheim) and crosslinked by a brief exposure to a 302 nm UV light. Hybridization probes were isolated VEGF cDNA or GADPH cDNA fragments labeled with PCR DIG Probe Synthesis Kit (Roche Molecular Biochemicals, Germany). The membranes were incubated at 421C for 4 h in a prehybridization buffer and then hybridized with the DIG-labeled VEGF probe for 16 h at 601C. Blots were washed at high stringency (0.5 Â SSC-0.1% SDS at 681C) and exposed to Kodak BioMax film (Eastman Kodak Co.). The specific bands were visualized with an enhanced chemiluminescent detection system (ECL; Boehringer Mannheim).
Western blot analysis
Protein extraction from tissue samples was performed as described previously (Wei et al., 2001b) . A 50 mg protein sample was separated by 12.5% SDS-PAGE, transferred onto polyvinylidene difluoride (PVDF) membrane, and immunoblotted with various antibodies. Bound antibodies were detected using appropriate peroxidase-coupled secondary antibodies, followed by an enhanced chemiluminescent detection system (ECL, Boehringer Mannheim).
Reporter gene assays
Two plasmids were kindly provided by Dr Amit Maity (University of Pennsylvania, USA). One contains 1.5 kb of the VEGF promoter subcloned into the reporter pGL3-Basic. The other contains 1.2 kb of the VEGF promoter, which is lacking the HIF-1 binding site, also in pGL3-Basic. C33A cells (5 Â 10 5 ) were transient transfected with 5 mg of these plasmids by Transfast Transfection Reagent (Promega). We used cotransfection with pSV--galactosidase, and data normalizations after all transient transfections were carried out using triplicate cultures, repeating every cotransfection protocol at least three times. The transient tranfected cells were then serum starved for 16 h and then treated with 250 mm CoCl 2 or 50 ng/ ml IL-6 for 6 h. Cell lysate luciferase activity was determined using the Luciferase Enzyme Assay System (Promega).
